Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of “Buy” from Brokerages

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) have been assigned a consensus rating of “Buy” from the ten brokerages that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $11.50.

Several research firms have recently weighed in on CATX. BMO Capital Markets set a $11.00 price objective on shares of Perspective Therapeutics and gave the company an “outperform” rating in a research report on Tuesday. Bank of America lowered their price target on Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Friday, August 14th. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, May 5th. BTIG Research reiterated a “buy” rating on shares of Perspective Therapeutics in a research report on Friday, July 24th. Finally, Piper Sandler dropped their target price on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. lifted its holdings in shares of Perspective Therapeutics by 184.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after acquiring an additional 5,475 shares during the last quarter. Aigen Investment Management LP bought a new position in shares of Perspective Therapeutics during the 4th quarter valued at $28,000. nVerses Capital LLC bought a new position in shares of Perspective Therapeutics during the 4th quarter valued at $31,000. Abel Hall LLC bought a new stake in Perspective Therapeutics in the first quarter worth $49,000. Finally, Engineers Gate Manager LP purchased a new stake in Perspective Therapeutics during the fourth quarter valued at about $35,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Price Performance

Shares of NYSEAMERICAN CATX opened at $3.30 on Tuesday. Perspective Therapeutics has a 12 month low of $1.96 and a 12 month high of $6.16. The business has a 50-day moving average of $3.11 and a 200-day moving average of $3.94.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.03. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. The company had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.09 million. Analysts predict that Perspective Therapeutics will post -1.03 earnings per share for the current fiscal year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.